An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
Sponsor: AbbVie
Sponsor score: 60
ClinicalTrials ID:NCT03844048
This extension study provides venetoclax to subjects who have completed a prior trial, focusing on long-term safety. Eligible participants must have tolerated and benefited from venetoclax, with males refraining from sperm donation and females not pregnant or breastfeeding. Venetoclax is administered orally as film-coated tablets or tablets for suspension.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this extension study is to provide venetoclax and obtain long-term safety data for subjects who continue to tolerate and derive benefit from receiving venetoclax in ongoing studies.
Eligibility Criteria
Inclusion Criteria
- Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study drug.
- Male subject agrees to refrain from sperm donation.
- Female subjects must not be pregnant or breastfeeding.
Exclusion Criteria
- None.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| University of Arizona Cancer Center - Tucson /ID# 210548 | 85724 | Tucson | Arizona |
| UCLA Santa Monica Hematology Oncology /ID# 210551 | 90095 | Los Angeles | California |
| Ingalls Memorial Hosp /ID# 210553 | 60426 | Harvey | Illinois |
| Dana-Farber Cancer Institute /ID# 215360 | 02215 | Boston | Massachusetts |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132 | 48109 | Ann Arbor | Michigan |
| Dartmouth-Hitchcock Medical Center /ID# 210555 | 03756 | Lebanon | New Hampshire |
| Swedish Cancer Institute /ID# 213120 | 98104-3588 | Seattle | Washington |
Get This Program In Your Inbox
You can sign up and apply your patients for this program.